EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Application of Mesenchymal Stromal Cells and Their Exosomes in Neurodegenerative Diseases and Lysosomal Storage Diseases

Aisylu I Ayupova iD, Angelina S Sidorova, Ekaterina A Luzina, Albert A Sufianov, Galina Z Sufianova, Azat M Zaynutdinov, Albert A Rizvanov iD, Valeriya V Solovyeva iD

Cells · 2026

DOI: 10.3390/cells15171540 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Aisylu I Ayupova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia. Hauptthemen laut MEDLINE: Exosomes, Neurodegenerative Diseases, Mesenchymal Stem Cells, Lysosomal Storage Diseases. Die Arbeit nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Education and Science of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesenchymal stromal cells (MSCs) have emerged as a promising therapeutic platform for central nervous system disorders, including neurodegenerative diseases and lysosomal storage disorders (LSDs). This review examines MSC mechanisms of action—paracrine activity, immunomodulation, antioxidant effects, TFEB-mediated autophagy regulation, and enzymatic cross-correction in LSDs—while critically assessing translational challenges. We provide a comparative analysis of MSC sources, administration routes, dosing regimens, and safety profiles, with emphasis on hemocompatibility and thrombotic risks. The evidence base for MSC efficacy in amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and LSDs is systematically reviewed, highlighting both promising signals and limitations. MSC-derived extracellular vesicles are discussed as a cell-free alternative with improved safety and potential blood–brain barrier interaction. We propose an individualized monitoring framework integrating clinical scales, biomarkers, and neuroimaging. Despite preclinical promise, the field faces major hurdles: product standardization, optimal dosing, and the need for large, randomized controlled trials. The most rational path forward lies in combination strategies—MSCs as adjuncts to gene or enzyme replacement therapy—and engineered platforms for sustained delivery. This review provides a roadmap for translational decision-making and identifies critical gaps that must be addressed before MSC-based therapies can be integrated into routine neurological practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesNeurodegenerative DiseasesMesenchymal Stem CellsLysosomal Storage DiseasesMesenchymal Stem Cell TransplantationHumansAnimals

Stichwörter der Autor:innen

cell therapycross-correctionexosomesextracellular vesicleshemocompatibilityimmunomodulationlysosomal storage disordersmesenchymal stromal cellsneurodegenerative diseasesneuroinflammationtissue factor

Autor:innen und Institutionen

  • Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
  • Department of Neurosurgery, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119991 Moscow, Russia.
  • The Research and Educational Institute of Neurosurgery, Peoples' Friendship University of Russia, 117198 Moscow, Russia.
  • Department of Pharmacology, Tyumen State Medical University, 625023 Tyumen, Russia.
  • Medical and Sanitary Unit of the Kazan Federal University, 420043 Kazan, Russia.
  • Division of Medical and Biological Sciences, Academy of Sciences of the Republic of Tatarstan, 420111 Kazan, Russia.

ORCID-Profile: Aisylu I Ayupova, Albert A Rizvanov, Valeriya V Solovyeva

Förderung

  • The Ministry of Education and Science of the Russian Federation

Zitieren

APA

Ayupova, A. I., Sidorova, A. S., Luzina, E. A., Sufianov, A. A., Sufianova, G. Z., Zaynutdinov, A. M., Rizvanov, A. A., & Solovyeva, V. V. (2026). Application of Mesenchymal Stromal Cells and Their Exosomes in Neurodegenerative Diseases and Lysosomal Storage Diseases. Cells. https://doi.org/10.3390/cells15171540

Vancouver

Ayupova AI, Sidorova AS, Luzina EA, Sufianov AA, Sufianova GZ, Zaynutdinov AM, et al. Application of Mesenchymal Stromal Cells and Their Exosomes in Neurodegenerative Diseases and Lysosomal Storage Diseases. Cells. 2026. doi:10.3390/cells15171540

BibTeX
@article{Ayupova2026,
  author = {Ayupova, Aisylu I and Sidorova, Angelina S and Luzina, Ekaterina A and Sufianov, Albert A and Sufianova, Galina Z and Zaynutdinov, Azat M and Rizvanov, Albert A and Solovyeva, Valeriya V},
  title = {Application of Mesenchymal Stromal Cells and Their Exosomes in Neurodegenerative Diseases and Lysosomal Storage Diseases},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15171540}
}
Kostenlos starten →